🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
Hemab Therapeutics Holdings, Inc. (COAG)
NASDAQ: COAG · Real-Time Price · USD
39.29
-0.57 (-1.43%)
Nov 20, 2026, 4:00 PM EST - Market closed

COAG Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024
Period Ending
Sep '26 Dec '25 Dec '24
Selling, General & Admin
17.3610.498.97
Research & Development
82.5459.6341.41
Operating Expenses
99.970.1250.38
Operating Income
-99.9-70.12-50.38
Interest & Investment Income
8.411.973.74
Other Non Operating Income (Expenses)
-0.234.01-1.88
Pretax Income
-92.81-64.14-48.52
Income Tax Expense
0.66-0.230.19
Net Income
-93.47-63.91-48.71
Net Income to Common
-93.47-63.91-48.71
Net Income Growth
---
Shares Outstanding (Basic)
2011
Shares Outstanding (Diluted)
2011
Shares Change
---
EPS (Basic)
-4.72-67.56-51.49
EPS (Diluted)
-4.72-67.56-51.49
EPS Growth
---

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024
Period Ending
Sep '26 Dec '25 Dec '24
Free Cash Flow
-89.4-61.49-45.87
Free Cash Flow Per Share
-4.51-65.00-48.49
EBITDA
-99.6-69.82-50.14
D&A For EBITDA
0.30.30.25
EBIT
-99.9-70.12-50.38
SEC Filings: 10-K · 10-Q